Cross-cultural adaptation, validation, and the reliability of the Sleep-Related Behaviors Questionnaire in patients with multiple sclerosis

Purpose Examining sleep-related behavioral disorder strategies in detail for MS patients provides an essential assessment to address specific disease findings. The aim of the study was to demonstrate the reliability and validity of the Turkish Sleep-Related Behaviors Questionnaire in patients with multiple sclerosis (MS). Methods A total of 100 MS patients were filled Sleep-Related Behaviors Questionnaire (SRBQ), Beck Depression Inventory (BDI), Insomnia Severity Index (ISI), and Pittsburgh Sleep Quality Index (PSQI). One week later, 30 randomly selected patients were refilled the SRBQ. The test-retest reliability, internal consistency, and contruct validity were determined. Results The mean age of the individuals included in the study was 38.9 +/- 11.0 years. The ICC value of the reproducibility of SRBQ was calculated as 0.877 (CI: 0.74-0.94). The test-retest reliability of the SRBQ was excellent (ICC > 0.80). Cronbach's alpha value of the SRBQ was 0.877, which indicates excellent consistency. The SRBQ had correlation coefficients of 0.573, 0.509, and 0.523 with ISI, PSQI, and BDI, respectively. The SRBQ had high validity (r > 0.50, p < 0.01). Conclusion The Turkish SRBQ was found to be valid and reliable in patients with MS. Owing to the long but comprehensive nature of the SRBQ, a low-cost detailed measurement could be obtained in clinical practice

Cross-cultural adaptation, reliability and validity of the Turkish version of the Fear of Relapse Scale (FoR) in individuals with multiple sclerosis

Objective: The study aimed to translate and cross-culturally adapt the Fear of Relapse Scale (FoR) into Turkish and determine its psychometric properties. Methods: International guidelines were used for the translation and adaptation process. The patients were asked to fill the FoR, Intolerance of Uncertainty (IUS-12) and Depression Anxiety and Stress Scale (DASS-21). One week later, participants refilled the FoR. The test-retest reliability, internal consistency, and construct validity of the FoR were analyzed. Results: A total of 101 MS patients (37.6 +/- 10.0 years, 81.2% women) were included in the research. The test retest reliability of the FoR was excellent (ICC:0.883; CI:0.64-0.92). The reproducibility of the items of the FoR ranged from 0.2 to 0.8. The Cronbach's alpha coefficient of the FoR was 0.914. The internal consistency of the items was ranged between 0.90 and 0.91 The relationship between FoR with IUS-12, DASS-21 (depression), DASS-21 (anxiety), DASS-21 (stress) was 0.609, 0.641, 0.648 and 0.631, respectively. The correlation coefficients were greater than 0.50 (p 0.01). Conclusion: The Turkish version of the FoR is a reliable and valid tool to measure relapse fear in patients with MS

The reliability and validity of the Turkish version of the multiple sclerosis impact scale-29

Background/aim: The purpose of the study was to cross-culturally adapt the Multiple Sclerosis Impact Scale-29 (MSIS-29) into Turkish and evaluate its reliability and validity in patients with Multiple Sclerosis (MS). Materials and methods: A total of 119 individuals with MS were enrolled in the research. The neurologist classified the patients with Expanded Disability Status Scale (EDSS). In the initial evaluation, patients completed the Multiple Sclerosis Impact Scale-29 (MSIS-29), the Multiple Sclerosis International Quality of Life (MusiQoL), EuroQol-5D-3L (EQ-5D-3L), and Beck Depression Scale (BDS), respectively one week later, the MSIS-29 evaluation was repeated. Internal consistency, test-retest reliability, and construct validity were assessed, separately. Results: The mean age of the total sample was 38.2 +/- 10.6 years. The test-retest reliability of both subscores of the MSIS-29 was excellent (>0.80). Internal consistency of the MSIS-29 physical and psychological score was 0.968 and 0.914, respectively. Both of the subscores had excellent internal consistency (>0.80). There was a strong relationship between MSIS-29 physical score with MusiQoL, EQ-5D-3L (index), EQ-5D-3L (VAS), and BDS scores (p 0.50). MSIS-29 physical was moderately related to EDSS (p 0.50). On the other hand, there was a weak correlation between MSIS-29 psychological score and EDSS (p < 0.01, r = 0.300). Conclusion: Turkish version of the MSIS-29 is a reliable and valid tool in individuals with MS

Clinical Features and Course in Pediatric Onset Multiple Sclerosis

WOS: 000312600000015Objective: Multiple Sclerosis is uncommon in children and adolescents. Two to 5 % of all patients with MS have onset before age 16. Although the clinical profile of MS appears similar to adults some features may differ. The disease may lead to significant disability at a younger age. Our aim is to determine the clinical features and, disease course in pediatric onset multiple sclerosis. Methods: In this study, we evaluated 21 patients with pediatric onset (before age 18). The records of patients were reviewed retrospectively. The following variables were evaluated; sex, age at onset, presenting symptoms, disease course, relapse rate, immunomodulatory treatment. Results: Twenty one patients were included to study. The mean age at onset was 15.2 (ranged 8-17). The female/male ratio was 1.3. The median follow up period was 5 years. The major presenting symptoms were pyramidal (9 patients), brainstem (8 patients) and optic neuritis (4 patients). The initial disease course was relapsing remitting in 19 patients but in 3 patients, secondary progression was observed before age 30. Two patients were with clinically isolated syndrome. Nineteen patients were treated with immunomodulatory drugs. In 4 patients Mitoxantrone was used because of progressive course and relapses. Conclusion: The clinical presentation of multiple sclerosis with pediatric onset is usually benign but in the long term, patients with pediatric onset can become disabled at a younger age

Clinical and Histopathological Study of Patients With Mitochondrial Abnormalities

WOS: 000312600000016Objective: Mitochondrial diseases are clinically heterogenous group of disorders with widely varying clinical features. Diagnosis can be difficult and requires synthesis of clinical, biochemical, histopathological and molecular data. These investigations may not be available in most medical centers. Muscle biopsy provides an important information to confirm a mitochondrial disease. Ragged red fibers and cytochrome oxidase negative fibers are the morphological hallmark of mitochondrial diseases. In this study, we aimed to analyze clinical features and histopathological findings of patients with mitochondrial abnormalities on muscle biopsy. Methods: We retrospectively evaluated demographic and neurologic features, presenting symptoms, additional systemic manifestations, syndromic features of patients with mitochondrial abnormalities on muscle biopsy, according to diagnostic criteria for mitochondrial cytopathies. Results: Among 936 muscle biopsy sample, 118 showed mitochondrial abnormalities. Eighty four patients were considered as primary mitochondrial disease based on clinical and histopathologic features. The diagnosis of 34 patients was nonmitochondrial diseases according to their clinical features and additional histopathologic findings. The most common syndrome was chronic progressive external ophtalmoplegia in 61 patients. Fifteen patients had isolated proximal myopathy and 4 patients had Kearns Sayre syndrome, 2 patients had SANDO, 1 patient had MNGIE, 1 patient had MLASA. Conclusion: Mitochondrial abnormalities occur in both mitochondrial diseases and many nonmitochondrial diseases. The majority of patients with primary mitochondrial disorders have ophtalmologic abnormalities or neuromuscular manifestations. The accurate diagnosis of mitochondrial diseases relies on a multidisciplinary approach and muscle biopsy is useful in both accurate diagnosis and differential diagnosis

Juvenile myasthenia gravis: Comparison of pre and postpubertal cases

12th International Congress of Neuroimmunology (ISNI) -- NOV 09-13, 2014 -- Mainz, GERMANYWOS: 00034519210010

Assessment of Olfaction and Gustation in Multiple Sclerosis: Correlation with Cognition

68th Annual Meeting of the American-Academy-of-Neurology (AAN) -- APR 15-21, 2016 -- Vancouver, CANADAWOS: 000411279005237Amer Acad Neuro

Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis

WOS: 000444552800005PubMed ID: 30138155Background: Adherence to medication treatment in patients with multiple sclerosis (MS) is important to increase its effectiveness, reduce patient disability, prevent attacks, and increase the quality of life. Aim: This study investigated factors that influence adherence to disease-modifying therapy in patients with MS. Methods: This descriptive study was conducted with 198 patients with MS who met the inclusion criteria and agreed to participate between July 2016 and February 2017. Data were collected using an Individual Identification Form that included sociodemographic characteristics, the Multiple Sclerosis Treatment Adherence Questionnaire, the Fatigue Severity Scale, the Self-Efficacy Scale, and the Brief COPE. Results: We found that 59.6% of the patients were adherent to therapy. Patients were significantly more adherent to Avonex than other treatments, and memory problems was the most common reason for missing or forgetting medication in nonadherent patients. There was a significant difference between medication adherence and some sociodemographic characteristics and disease characteristics (P .05). Conclusion: Patients' adherence to medication treatment was low and may be associated with social, physical, and cognitive measures